What is the bonus history of the Shree Ganesh Bio?

Shree Ganesh Bio issued a 1:1 bonus on April 27, 2022, with a record date of April 28, 2022, granting shareholders one additional share for each share owned.

Shree Ganesh Bio has a recent bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of April 27, 2022, and the record date was April 28, 2022. This means that shareholders received one additional share for every share they owned as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Shree Ganesh Bio declared dividend?

No Dividend History Available

Who are the peers of the Shree Ganesh Bio?

Shree Ganesh Bio's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Drugs, Colinz Labs, Veerhealth Care, and Vineet Laborator. Shree Ganesh Bio has below-average management risk and growth, with a 1-year return of -23.48%, higher than Vineet Laborator's -46.35% but lower than all other peers.

Peers: The peers of Shree Ganesh Bio are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Drugs, Colinz Labs, Veerhealth Care, and Vineet Laborator.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vineet Laborator. Below Average management risk is noted at Shree Ganesh Bio, Concord Drugs, Colinz Labs, Veerhealth Care, and Vilin Bio Med. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Shree Ganesh Bio, Divi's Lab., Torrent Pharma, Concord Drugs, Colinz Labs, Veerhealth Care, Vineet Laborator, and Vilin Bio Med. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted at Shree Ganesh Bio, Colinz Labs, and Veerhealth Care, and Below Average capital structure is found at Concord Drugs, Vineet Laborator, and Vilin Bio Med.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the peer with the lowest is Vineet Laborator at -46.35%. Shree Ganesh Bio's 1-year return is -23.48%, which is higher than Vineet Laborator's but lower than all other peers. Additionally, Concord Drugs, Veerhealth Care, and Vineet Laborator have negative six-month returns.

Is Shree Ganesh Bio overvalued or undervalued?

As of February 14, 2024, Shree Ganesh Bio is considered overvalued and risky, with a PE Ratio of 35.48, negative EV to EBIT, and a PEG Ratio of 0.00, reflecting operational challenges and a significant underperformance of -23.93% over the past year compared to a 7.61% gain in the Sensex.

As of 14 February 2024, the valuation grade for Shree Ganesh Bio has moved from expensive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued. Key ratios reflect this concern, with a PE Ratio of 35.48, an EV to EBIT of -33.78, and a Price to Book Value of 0.56, suggesting that the stock price is not justified by its earnings or asset value.<BR><BR>In comparison to peers, Shree Ganesh Bio's PE ratio stands out against industry benchmarks, while its negative EV to EBIT and EV to EBITDA ratios highlight operational challenges. Notably, the company has a PEG Ratio of 0.00, indicating no growth expectations, which further supports the overvaluation assessment. Over the past year, Shree Ganesh Bio has underperformed significantly, with a stock return of -23.93% compared to a 7.61% gain in the Sensex, reinforcing the notion that the stock may not be a sound investment at its current price.

What is the technical trend for Shree Ganesh Bio?

As of March 21, 2025, Shree Ganesh Bio's technical trend has shifted to a bearish stance with weak strength, indicated by bearish MACD, RSI, moving averages, and KST across multiple timeframes, while Bollinger Bands suggest a mildly bearish trend.

As of 21 March 2025, the technical trend for Shree Ganesh Bio has changed from mildly bearish to bearish. The current stance is bearish with a weak strength. Key indicators driving this include a bearish MACD on the weekly chart, a bearish RSI on the weekly chart, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on both the weekly and monthly charts, while Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. The Dow Theory shows no trend on both weekly and monthly levels, further supporting the bearish outlook.

Who are in the management team of Shree Ganesh Bio?

As of March 2022, the management team of Shree Ganesh Bio includes Aman Patel (Chairman & Wholetime Director), Kishan Nityanand Naidu, Harshad Rathod, Amrutaben Solanki (Directors), Namita Acharya (Company Secretary & Compliance Officer), and independent directors Sombir Singh, Chandni Solanki, and Nimeshkumar Parmar. This team oversees the company's operations and compliance.

As of March 2022, the management team of Shree Ganesh Bio includes the following individuals:<BR><BR>1. Sombir Singh - Independent Director<BR>2. Chandni Solanki - Independent Director<BR>3. Kishan Nityanand Naidu - Director<BR>4. Namita Acharya - Company Secretary & Compliance Officer<BR>5. Harshad Rathod - Director<BR>6. Aman Patel - Chairman & Wholetime Director<BR>7. Amrutaben Solanki - Director<BR>8. Nimeshkumar Parmar - Independent Director<BR><BR>This team comprises a mix of independent directors and company executives responsible for overseeing the company's operations and compliance.

What does Shree Ganesh Bio do?

Shree Ganesh Biotech India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 30 Cr and a net loss of 10 Cr for the quarter ending March 2025. The company has a market cap of INR 33 Cr and key metrics include a P/E ratio of 33.00 and a return on equity of 0.60%.

Overview: <BR>Shree Ganesh Biotech India Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated on September 2, 1982, originally as 'S.P. Commercial Co. Limited'. It received its Certificate of Commencement of Business on September 14, 1982. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 33 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 52 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 0.60% <BR>Price to Book: 0.52 <BR><BR>Contact Details: <BR>Address: 6 Flr Premises-602 Mahavir Apt, 2 Aushutosh Mukherjee Road Kolkata West Bengal : 700020 <BR>Email: shreeganeshbiotechindialtd@gmail.co <BR>Website: http://shreeganeshbiotech.tech/

Who are the top shareholders of the Shree Ganesh Bio?

The top shareholders of Shree Ganesh Bio are primarily individual investors, holding 95.24% of the shares, while one Foreign Institutional Investor and New Era Fund Limited each hold 1.42%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Shree Ganesh Bio include a significant portion of individual investors, who hold 95.24% of the shares. Among institutional investors, there is one Foreign Institutional Investor (FII) that holds 1.42% of the shares. The highest public shareholder is New Era Fund Limited, which also holds 1.42%. Notably, there are no pledged promoter holdings, and no mutual funds are currently invested in the company.

How big is Shree Ganesh Bio?

As of 24th July, Shree Ganesh Biotech India Ltd has a market capitalization of 33.00 Cr and reported net sales of 22.96 Cr and net profit of 0.38 Cr over the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Shree Ganesh Biotech India Ltd has a market capitalization of 33.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 22.96 Cr, while the sum of Net Profit for the same period is 0.38 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2024. Shareholder's Funds stand at 62.98 Cr, and Total Assets are valued at 73.62 Cr.

When is the next results date for Shree Ganesh Bio?

The next results date for Shree Ganesh Bio is 08 November 2025.

The next results date for Shree Ganesh Bio is scheduled for 08 November 2025.

Should I buy, sell or hold Shree Ganesh Bio?

Are Shree Ganesh Bio latest results good or bad?

The latest results for Shree Ganesh Biotech are concerning, showing a 61.11% decline in net sales and a 96.88% drop in net profit year-over-year, leading to a "Strong Sell" rating from analysts due to significant operational challenges and poor financial performance.

The latest results for Shree Ganesh Biotech are quite concerning. In the second quarter of FY26, the company reported net sales of just ₹0.77 crores, which is a staggering 61.11% decline compared to the same quarter last year. Furthermore, net profit was only ₹0.01 crores, down 96.88% year-over-year. This marginal profit was heavily reliant on other income, highlighting the company's struggle to generate sustainable operational profits.<BR><BR>The operating margin, excluding other income, was deeply negative at -50.65%, indicating significant operational challenges. The company's return on equity (ROE) is extremely low at 0.74%, suggesting poor capital efficiency.<BR><BR>Overall, the financial performance reflects a deteriorating situation, with substantial revenue and profit declines, and persistent operating losses. The absence of promoter holding and negligible institutional interest further complicates the outlook, leading to a "Strong Sell" rating from analysts. Given these factors, the latest results can be classified as bad, indicating serious concerns about the company's viability moving forward.

How has been the historical performance of Shree Ganesh Bio?

Shree Ganesh Bio has experienced a significant decline in financial performance, with net sales dropping from 62.45 Cr in March 2023 to 22.96 Cr by March 2025, and profit after tax decreasing from 2.53 Cr to 0.28 Cr during the same period. Additionally, cash flow from operating activities turned negative in March 2025, indicating operational challenges.

Answer:<BR>The historical performance of Shree Ganesh Bio shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Shree Ganesh Bio's net sales peaked in March 2023 at 62.45 Cr, but have since declined to 22.96 Cr by March 2025. The total operating income followed a similar trend, decreasing from 72.64 Cr in March 2022 to 22.96 Cr in March 2025. Raw material costs have also decreased, from 68.84 Cr in March 2022 to 22.64 Cr in March 2025. The company reported an operating profit (PBDIT) of 0.39 Cr in March 2025, down from 3.49 Cr in March 2022, indicating a decline in profitability. Profit after tax has also decreased significantly from 2.53 Cr in March 2022 to 0.28 Cr in March 2025. The total liabilities have decreased from 93.55 Cr in March 2022 to 63.49 Cr in March 2025, while total assets have similarly declined from 93.55 Cr to 63.49 Cr over the same period. The cash flow from operating activities turned negative in March 2025 at -10.00 Cr, contrasting with positive cash flows in previous years. Overall, the financial performance of Shree Ganesh Bio has shown a downward trend in sales, profits, and cash flow, reflecting challenges in its operational efficiency and market conditions.

Which are the latest news on Shree Ganesh Bio?

Why is Shree Ganesh Bio falling/rising?

As of 03-Dec, Shree Ganesh Biotech India Ltd's stock price is currently at 0.64, reflecting a 1.59% increase today and a positive return over the past week. However, it has seen significant declines year-to-date and over the past year, indicating a longer-term downward trend despite today's short-term gains.

As of 03-Dec, Shree Ganesh Biotech India Ltd's stock price is rising, currently at 0.64, with a change of 0.01, representing an increase of 1.59%. This rise is notable as the stock has outperformed its sector by 2.87% today. Additionally, over the past week, the stock has shown a positive return of 1.59%, contrasting with a decline of 0.59% in the Sensex, indicating relative strength against the broader market.<BR><BR>However, it is important to note that the stock has experienced significant declines over longer periods, with a year-to-date drop of 38.46% and a one-year decline of 40.74%. The stock's performance today is also characterized by lower investor participation, as evidenced by a delivery volume of 4.26 lacs on December 2, which has decreased by 46.14% compared to the 5-day average. Despite this drop in participation, the current price movement reflects a short-term positive trend, although it remains below the longer-term moving averages, suggesting that the overall trend may still be downward in the longer term.